Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Depression Clinical Trials

A listing of Depression medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (35) clinical trials

The California Clinical Trials Medical Group managed by PAREXEL located in Glendale, CA is looking for people with depression to participate in a research study that will evaluate the efficacy of a new investigational medication for the treatment of depression. The study may involve up to 2 screening visits, 5 ...

Phase

The PAREXEL® Early Phase Unit located in Glendale, CA is looking for people with depression to participate in a clinical research study. TO QUALIFY YOU MUST BE: Male or female 18-59 years of age Have an existing diagnosis of Major Depressive Disorder Stable on antidepressants for 6 weeks The study ...

Phase

The PAREXEL® Early Phase Unit located in Glendale, CA is looking for people with depression to participate in a clinical research study. To qualify you must be: male or female,18-59 years old, have an existing diagnosis of Major Depressive Disorder, stable on antidepressants for 6 weeks. The study may involve ...

Phase

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 [HDRS17], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 [HAM-D6]) differs across different levels of hyper-arousal status (characterized ...

Phase

NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as treatment-resistant major depression (TRMD). New treatments for TRMD are needed, and one promising line of research are drugs known as ...

Phase

Ketamine for Relapse Prevention in Recurrent Depressive Disorder

Participants will be recruited at admission to St Patrick's University Hospital for treatment of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)-diagnosed recurrent unipolar depression and followed-up weekly to assess recovery according to standard criteria. Blood samples for epigenetic studies will be taken at baseline. Treatment-as-usual will ...

Phase

The Study About Mechanism of Transcranial Magnetic Stimulation Treatment of Depression Using Medical Imaging

The advantages of 3D T1 WI are thin slice scanno interval, scanning fast and three-dimension reconstruction in any orientation compared with 2D SE. It is not easy to miss small lesions, and shows normal anatomy and lesions more objectively and more accurately. Doppler tissue imaging (DTI) can reflect white matter ...

Phase

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese heathy subjects. Part of the participants will receive Ammoxetine Hydrochloride Enteric-coated Tablets, while the other part will receive placebo.

Phase

CM Delivered PST in LLD Pilot

The study will be a single-centre, open-label, longitudinal, pragmatic, pilot trial. Research participants at this site will be 40 men and women between the ages of 60 and 85 who have mild to moderate major depressive disorder (MDD). Participants will be recruited from primary, secondary and tertiary care centres in ...

Phase

A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder

The primary purpose of this study is to evaluate the effect of a single 84-milligram (mg) dose of intranasal esketamine compared to placebo, on next day driving performance and repeated administration of 84 mg intranasal esketamine on same-day driving performance as assessed by the mean difference of standard deviation of ...

Phase